Journal articles on the topic 'Paris (France) Corporation des ménétriers'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 24 journal articles for your research on the topic 'Paris (France) Corporation des ménétriers.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Métayer, Christine. "Normes graphiques et pratiques de l’écriture: Maîtres écrivains et écrivains publics à Paris aux XVIIe et XVIIIe siècles." Annales. Histoire, Sciences Sociales 56, no. 4-5 (October 2001): 881–901. http://dx.doi.org/10.3406/ahess.2001.279992.
Full textMétayer, Christine. "Normes graphiques et pratiques de l’écriture: Maîtres écrivains et écrivains publics à Paris aux XVIIe et XVIIIe siècles." Annales. Histoire, Sciences Sociales 56, no. 4-5 (October 2001): 881–901. http://dx.doi.org/10.1017/s0395264900033291.
Full textGendrot, Monique, and Alain Gebert. "Missions en faveur de la protection des Langues des Signes en danger dans la région de l’Océan Indien: la Langue des Signes Mauricienne (République de Maurice) et de la Langue des Signes Seychelloise (République des Seychelles), en lien avec le Pôle LSF de l’INJS de Paris." MOARA – Revista Eletrônica do Programa de Pós-Graduação em Letras ISSN: 0104-0944 1, no. 45 (September 2, 2016): 46. http://dx.doi.org/10.18542/moara.v1i45.3706.
Full textMcPherson, Michael. "History of Economic Thought, Methodology, and Heterodox Approaches: Worldly Philosopher: The Odyssey of Albert O. Hirschman." Journal of Economic Literature 51, no. 4 (December 1, 2013): 1185–87. http://dx.doi.org/10.1257/jel.51.4.1183.r2.
Full textFrydman, René, Hervé Fernandez, Frédéric Troalen, Pascal Ghillani, Jean Daniel Rainhorn, and Dominique Bellet. "Phase I clinical trial of monoclonal anti-human chorionic gonadotropin antibody in women with an ectopic pregnancy**Supported in part by a grant from Lafon Corporation, Paris, France." Fertility and Sterility 52, no. 5 (November 1989): 734–38. http://dx.doi.org/10.1016/s0015-0282(16)61023-3.
Full textVan Den Neste, Eric, Norbert Schmitz, Nicolas Mounier, Devinder Gill, Marek Trneny, Noel Milpied, John A. Radford, et al. "Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study." Blood 126, no. 23 (December 3, 2015): 517. http://dx.doi.org/10.1182/blood.v126.23.517.517.
Full textCrenshaw, Brian S., Samuel R. Ward, Christopher B. Granger, Amanda L. Stebbins, Eric J. Topol, and Robert M. Califf. "Atrial Fibrillation in the Setting of Acute Myocardial Infarction: The GUSTO-I Experience fn1fn1This study was funded by grants from Genentech, South San Francisco, California; Bayer Corporation, New York, New York; CIBA-Corning, Medfield, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France." Journal of the American College of Cardiology 30, no. 2 (August 1997): 406–13. http://dx.doi.org/10.1016/s0735-1097(97)00194-0.
Full textCorash, Laurence. "Safety Profile of Platelet Components Treated with Amotosalen-UVA Pathogen Inactivation Transfused in Routine Use: Multi-Year Active Hemovigilance." Blood 120, no. 21 (November 16, 2012): 2278. http://dx.doi.org/10.1182/blood.v120.21.2278.2278.
Full textSgarbossa, Elena B., Sergio L. Pinski, Eric J. Topol, Robert M. Califf, Alejandro Barbagelata, Shaun G. Goodman, Kathy B. Gates, et al. "Acute Myocardial Infarction and Complete Bundle Branch Block at Hospital Admission: Clinical Characteristics and Outcome in the Thrombolytic Era fn1fn1This study was supported by grants from Bayer Corporation, New York, New York; Genentech, Inc., South San Francisco, California; CIBA-Corning, Medford, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France." Journal of the American College of Cardiology 31, no. 1 (January 1998): 105–10. http://dx.doi.org/10.1016/s0735-1097(97)00446-4.
Full textDubois, Sydney, Bruno Tesson, Pierre-Julien Viailly, Thierry Molina, Christiane Copie-Bergman, Sylvain Mareschal, Elodie Bohers, et al. "Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study." Blood 126, no. 23 (December 3, 2015): 1472. http://dx.doi.org/10.1182/blood.v126.23.1472.1472.
Full textGranger, Christopher B., Richard Becker, Russell P. Tracy, Robert M. Califf, Eric J. Topol, Karen S. Pieper, Allan M. Ross, Sherryn Roth, Costas Lambrew, and Edwin G. Bovill. "Thrombin Generation, Inhibition and Clinical Outcomes in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy and Heparin: Results From the GUSTO-I Trial fn1fn1This study was supported by Genentech, Inc., South San Francisco, California; Bayer Corporation, New York, New York; CIBA-Corning, Medfield, Massachusetts; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmaceuticals, Paris, France." Journal of the American College of Cardiology 31, no. 3 (March 1998): 497–505. http://dx.doi.org/10.1016/s0735-1097(97)00539-1.
Full textDíez, José G., and Marc Cohen. "Balancing Myocardial Ischemic and Bleeding Risks in Patients With Non-ST-Segment Elevation Myocardial Infarction††Conflicts of interest: Dr. Cohen has received grant and research support from Sanofi-Aventis, Paris, France; Merck & Company, Whitehouse Station, New Jersey; Datascope Corporation, Montvale, New Jersey; Bayer AG, Leverkeusen, Germany; AstraZeneca, Wilmington, Delaware; COR Therapeutics, Inc., San Francisco, California; Pfizer, Inc., New York, New York; and Guidant Corporation, Indianapolis, Indiana. He serves as a consultant for Datascope, Sanofi-Aventis, and AstraZeneca and is part of the speakers' bureaus of Merck & Company; Sanofi-Aventis; Schering-Plough Corporation, Kenilworth, New Jersey; and Bristol-Myers Squibb Company, New York, New York. He is not a major stock shareholder in any company. Dr. Diez serves as a consultant for Sanofi-Aventis. He is part of the speakers' bureaus of The Medicines Company, Parsippany, New Jersey; Sanofi-Aventis; and Schering-Plough Corporation. He is not a major stock shareholder in any company." American Journal of Cardiology 103, no. 10 (May 2009): 1396–402. http://dx.doi.org/10.1016/j.amjcard.2009.01.349.
Full textSpector, Peter, Matthew R. Reynolds, Hugh Calkins, Manu Sondhi, Yingxin Xu, Amber Martin, Catherine J. Williams, and Isabella Sledge. "Meta-Analysis of Ablation of Atrial Flutter and Supraventricular Tachycardia††Conflicts of interest: Dr. Spector is a consultant for Medtronic, Inc., Minneapolis, Minnesota; Biosense Webster, Inc.; and Boston Scientific Corporation, Natick, Massachusetts. Dr. Spector has received research grant support from Medtronic, Inc., and Biosense Webster, Inc. Dr. Reynolds is a consultant for Biosense Webster, Inc., and Sanofi-Aventis, Paris, France. Dr. Calkins is a consultant for Biosense Webster, Inc.; CryoCor, San Diego, California; Medtronic, Inc.; and ProRhythm, Inc., Ronkonkoma, New York. Drs. Sondhi, Xu, and Sledge and Ms. Martin and Ms. Williams were employees of United BioSource Corporation during the conduct of this study." American Journal of Cardiology 104, no. 5 (September 2009): 671–77. http://dx.doi.org/10.1016/j.amjcard.2009.04.040.
Full textLaBounty, Troy M., Richard B. Devereux, Fay Y. Lin, Jonathan W. Weinsaft, and James K. Min. "Impact of Coronary Computed Tomographic Angiography Findings on the Medical Treatment and Control of Coronary Artery Disease and Its Risk Factors††Conflicts of interest: Dr. Min has a research grant from GE Healthcare, Milwaukee, Wisconsin; is on the speaker's bureau for GE Healthcare; has a research grant from Vital Images, Minnetonka, Minnesota; and is a consultant for the Cordis Corporation, Miami Lakes, Florida. Dr. Devereux is a consultant for Merck & Company, Whitehouse Station, New Jersey; Novartis AG, Basel, Switzerland; Sanofi-Aventis, Paris, France; and Novo Nordisk A/S, Bagsværd, Denmark." American Journal of Cardiology 104, no. 7 (October 2009): 873–77. http://dx.doi.org/10.1016/j.amjcard.2009.05.024.
Full textStein, Evan A., Erik S. G. Stroes, George Steiner, Brendan M. Buckley, Alessandro M. Capponi, Tracy Burgess, Eric J. Niesor, David Kallend, and John J. P. Kastelein. "Safety and Tolerability of Dalcetrapib††Conflicts of interest: Dr. Stein has received grants for studies of lipid-modifying agents, has received consulting fees and honoraria for professional input regarding agents to modify lipid profile, and/or has delivered lectures for the American Association for Clinical Chemistry, Washington, District of Columbia; Abbott Laboratories, Abbott Park, Illinois; AstraZeneca, Wilmington, Delaware; the United States Food and Drug Administration, Washington, District of Columbia; F. Hoffmann-La Roche Ltd., Basel, Switzerland; Isis Pharmaceuticals, Inc., Carlsbad, California; Merck & Co., Whitehouse Station, New Jersey; the National Lipid Association, Jacksonville, Florida; Novartis International AG, Basel Switzerland; Reliant Pharmaceuticals, Inc., Liberty Corner, New Jersey; Daiichi Sankyo Co., Ltd., Tokyo, Japan; Schering-Plough Corporation, Kenilworth, New Jersey; Takeda Pharmaceutical Company Ltd., Osaka, Japan; and Wyeth, Madison, New Jersey. Dr. Stroes has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. and Novartis International AG. Dr. Steiner has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd.; Solvay, Brussels, Belgium; Ethypharm S.A., Saint-Cloud, France; and Merck Frosst Canada Ltd. (Kirkland, Quebec, Canada)/Schering-Plough Corporation. Dr. Buckley has received research grants from AstraZeneca; Merck Sharp & Dohme, Dublin, Ireland; and Pfizer, Inc., New York, New York. Dr. Buckley has received honoraria and consulting fees and/or delivered lectures for AstraZeneca; Bristol-Myers Squibb, New York, New York; F. Hoffmann-La Roche Ltd.; Novartis International AG; Pfizer, Inc.; and Sanofi-Aventis, Paris, France. Dr. Capponi has received consulting fees and honoraria from F. Hoffmann-La Roche Ltd. Dr. Burgess is an employee of Hoffmann-La Roche Inc., Nutley, New Jersey. Drs. Niesor and Kallend are employees of F. Hoffmann-La Roche Ltd. Dr. Kastelein has received research grants, honoraria, or consulting fees for professional input and/or has delivered lectures for Pfizer, Inc.; Merck Sharp & Dohme; F. Hoffmann-La Roche Ltd.; Novartis International AG; Isis Pharmaceuticals, Inc.; Kowa Pharmaceutical Company Ltd., Nagoya, Japan; Schering-Plough Corporation; and AstraZeneca." American Journal of Cardiology 104, no. 1 (July 2009): 82–91. http://dx.doi.org/10.1016/j.amjcard.2009.02.061.
Full textSakhuja, Rahul, Mary Keebler, Tai-Shuan Lai, Cara McLaughlin Gavin, Ranjan Thakur, and Deepak L. Bhatt. "Meta-Analysis of Mortality in Dialysis Patients With an Implantable Cardioverter Defibrillator††Disclosures: Dr. Bhatt has received research grants (directly to the institution) from Bristol-Myers Squibb, New York, New York; Eisai Inc., Woodcliff Lake, New Jersey; Ethicon, Inc., Somerville, New Jersey; Heartscape Technologies, Inc., Columbia, Maryland; Sanofi-Aventis, Paris, France; and The Medicines Company, Parsippany, New Jersey. Dr. Bhatt is a consultant for or member of the advisory boards (honoraria waived or donated to nonprofit organizations) of Arena Pharmaceuticals, Inc., San Diego, California; AstraZeneca PLC, London, United Kingdom; Bristol-Myers Squibb; Cardax Pharmaceuticals, Inc., Aiea, Hawaii; Centocor, Inc., Horsham, Pennsylvania; Cogentus Pharmaceuticals, Palo Alto, California; Daiichi Sankyo, Inc., Parsippany, New Jersey; Eisai Inc.; Eli Lilly and Company, Indianapolis, Indiana; GlaxoSmithKline PLC, London, United Kingdom; Johnson & Johnson, New Brunswick, New Jersey; Ortho-McNeil, Raritan, New Jersey; Medtronic, Inc., Minneapolis, Minnesota; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts; Otsuka Pharmaceutical Company, Ltd., Tokyo, Japan; ParinGenix, Inc., Weston, Florida; PDL BioPharma, Inc., Redwood City, California; Philips Medical Systems, Andover, Massachusetts; Portola Pharmaceuticals Inc., South San Francisco, California; Sanofi-Aventis; Schering-Plough Corporation, Kenilworth, New Jersey; The Medicines Company; and Vertex Pharmaceuticals, Inc., Cambridge, Massachusetts." American Journal of Cardiology 103, no. 5 (March 2009): 735–41. http://dx.doi.org/10.1016/j.amjcard.2008.11.014.
Full textNobles, Bill. "Use hierarchy for “liberating servant leadership” instead of controlling employees." Journal of Organization Design 8, no. 1 (November 18, 2019). http://dx.doi.org/10.1186/s41469-019-0061-x.
Full text"Language learning." Language Teaching 37, no. 1 (January 2004): 53–61. http://dx.doi.org/10.1017/s0261444804222133.
Full textArmitage, John. "The Uncertainty Principle." M/C Journal 3, no. 3 (June 1, 2000). http://dx.doi.org/10.5204/mcj.1846.
Full textMac Con Iomaire, Máirtín. "Coffee Culture in Dublin: A Brief History." M/C Journal 15, no. 2 (May 2, 2012). http://dx.doi.org/10.5204/mcj.456.
Full textAvram, Horea. "The Convergence Effect: Real and Virtual Encounters in Augmented Reality Art." M/C Journal 16, no. 6 (November 7, 2013). http://dx.doi.org/10.5204/mcj.735.
Full text"Buchbesprechungen." Zeitschrift für Historische Forschung: Volume 47, Issue 4 47, no. 4 (October 1, 2020): 663–808. http://dx.doi.org/10.3790/zhf.47.4.663.
Full textSee, Pamela Mei-Leng. "Branding: A Prosthesis of Identity." M/C Journal 22, no. 5 (October 9, 2019). http://dx.doi.org/10.5204/mcj.1590.
Full textWatson, Robert. "E-Press and Oppress." M/C Journal 8, no. 2 (June 1, 2005). http://dx.doi.org/10.5204/mcj.2345.
Full text